{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:00:33Z","timestamp":1784926833543,"version":"3.55.0"},"reference-count":105,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Brain metastases are a common complication among patients with non\u2013small cell lung cancer and are historically associated with significant morbidity and limited survival. Although surgery and radiation therapy remain essential pillars in the clinical management of brain metastases, the development of several pharmacologic agents with activity in the central nervous system has broadened the role of systemic therapies for treating brain metastases. There is accumulating evidence that, in the appropriate clinical scenarios, systemic therapies may be used to manage both intracranial and extracranial disease while delaying local therapy and mitigating potential treatment-related morbidity. Determining the optimal treatment approach requires careful consideration of the intracranial tumor burden, location of lesions, pathologic and molecular profile, local and systemic therapy options, and overall prognosis. This review will provide updates on the medical management of non\u2013small cell lung cancer brain metastases, with a focus on recent advances in systemic therapy options.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000840","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:29Z","timestamp":1784923229000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Medical Management of Non\u2013Small Cell Lung Cancer Brain Metastases in the Modern Era"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8764-8384","authenticated-orcid":false,"given":"Benjamin Y.","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology and Hematology"},{"name":"Department of Neurology, Yale School of Medicine"},{"name":"Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology and Hematology"},{"name":"Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260724","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20260724","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.10541","article-title":"Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma","volume":"94","author":"Schouten","year":"2002","journal-title":"Cancer"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"e43V3694","DOI":"10.1200\/EDBK_433694","article-title":"Navigating the complexities of brain metastases management","volume":"44","author":"Amouzegar","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cllc.2025.06.003","article-title":"A review of focal therapies for small cell lung cancer brain metastases","volume":"26","author":"Robinson","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11910-025-01412-y","article-title":"Leptomeningeal disease: current approaches and future directions","volume":"25","author":"Sener","year":"2025","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/GO.20.00629","article-title":"Assessment of brain metastasis at diagnosis in non\u2013small-cell lung cancer: a prospective observational study from North India","volume":"7","author":"Naresh","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/j.jtho.2022.09.096","article-title":"PP01.70 prevalence, treatment patterns, and survival by age in patients diagnosed with metastatic non-small cell lung cancer (mNSCLC) and brain metastases (BM) in the United States","volume":"18","author":"Danese","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"e1075","DOI":"10.1093\/oncolo\/oyad170","article-title":"Clinicogenomic factors and treatment patterns among patients with advanced non\u2013small cell lung cancer with or without brain metastases in the United States","volume":"28","author":"Smyth","year":"2023","journal-title":"Oncol"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/j.lungcan.2004.07.967","article-title":"Treatment of brain metastases from lung cancer: chemotherapy","volume":"45","author":"Schuette","year":"2004","journal-title":"Lung Cancer"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R14-20260724","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non\u2013small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"e2200621","DOI":"10.1200\/PO.22.00621","article-title":"Incidence of brain metastases and preliminary evidence of intracranial activity with sotorasib in patients with KRASG12C-mutant non\u2013small-cell lung cancer","volume":"7","author":"Lamberti","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejca.2021.10.006","article-title":"Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations","volume":"159","author":"Vassella","year":"2021","journal-title":"Eur J Cancer"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/cncr.32372","article-title":"Genes associated with increased brain metastasis risk in non\u2013small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non\u2013small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)","volume":"125","author":"Wang","year":"2019","journal-title":"Cancer"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","article-title":"Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma","volume":"52","author":"Shih","year":"2020","journal-title":"Nat Genet"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.lungcan.2009.06.018","article-title":"Activity of pemetrexed on brain metastases from non-small cell lung cancer","volume":"68","author":"Bearz","year":"2010","journal-title":"Lung Cancer"},{"key":"R24-20260724","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann Oncol"},{"key":"R25-20260724","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/neuonc\/nos004","article-title":"Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma","volume":"14","author":"Bailon","year":"2012","journal-title":"Neuro-Oncol"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#","article-title":"Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study","volume":"85","author":"Franciosi","year":"1999","journal-title":"Cancer"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJMe2514042","article-title":"Navigating the evolving landscape of EGFR-mutated NSCLC","volume":"394","author":"Herbst","year":"2026","journal-title":"N Engl J Med"},{"key":"R28-20260724","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","article-title":"Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma","volume":"82","author":"Iuchi","year":"2013","journal-title":"Lung Cancer"},{"key":"R29-20260724","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"\u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro-Oncol"},{"key":"R30-20260724","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","article-title":"Management of brain metastases in tyrosine kinase inhibitor\u2013na\u00efve epidermal growth factor receptor\u2013mutant non\u2013small-cell lung cancer: a retrospective multi-institutional analysis","volume":"35","author":"Magnuson","year":"2017","journal-title":"J Clin Oncol"},{"key":"R31-20260724","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"R32-20260724","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R33-20260724","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2017","journal-title":"N Engl J Med"},{"key":"R34-20260724","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","journal-title":"N Engl J Med 2019"},{"key":"R35-20260724","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR -mutated advanced non\u2013small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"R36-20260724","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"R37-20260724","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N Engl J Med"},{"key":"R38-20260724","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor\u2013mutated advanced non\u2013small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J Clin Oncol"},{"key":"R39-20260724","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","article-title":"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1\u20132 study","volume":"20","author":"Ahn","year":"2019","journal-title":"Lancet Oncol"},{"key":"R40-20260724","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaoncol.2024.2640","article-title":"Lazertinib in EGFR-variant non\u2013small cell lung cancer with CNS failure to prior EGFR tyrosine kinase inhibitors","volume":"10","author":"Hong","year":"2024","journal-title":"JAMA Oncol"},{"key":"R41-20260724","doi-asserted-by":"crossref","first-page":"103505","DOI":"10.1016\/j.jtho.2025.10.012","article-title":"Phase 2 study of amivantamab plus lazertinib in previously-treated patients with EGFR mutant lung cancers with brain and leptomeningeal metastases","volume":"21","author":"Chen","year":"2026","journal-title":"J Thorac Oncol"},{"key":"R42-20260724","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study \u2606","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"R43-20260724","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"R44-20260724","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab\u2013lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"R45-20260724","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO-24-02835","article-title":"Amivantamab plus lazertinib in atypical EGFR-mutated advanced non\u2013small cell lung cancer: results from CHRYSALIS-2","volume":"44","author":"Tomasini","year":"2026","journal-title":"J Clin Oncol"},{"key":"R46-20260724","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-22-3497","article-title":"Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations","volume":"29","author":"Grant","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R47-20260724","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"R48-20260724","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"R49-20260724","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non\u2013small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J Clin Oncol"},{"key":"R50-20260724","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R51-20260724","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"R52-20260724","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann Oncol"},{"key":"R53-20260724","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol"},{"key":"R54-20260724","doi-asserted-by":"crossref","first-page":"vi437","DOI":"10.1093\/annonc\/mdw383.63","article-title":"1263P Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)","volume":"27","author":"Barlesi","year":"2016","journal-title":"Ann Oncol"},{"key":"R55-20260724","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase\u2013positive non\u2013small-cell lung cancer: a randomized, multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"R56-20260724","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R57-20260724","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2019.11.004","article-title":"Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial","volume":"15","author":"Huber","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R58-20260724","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1158\/1078-0432.CCR-17-2398","article-title":"Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I\/II, multicenter study","volume":"24","author":"Horn","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R59-20260724","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"R60-20260724","doi-asserted-by":"crossref","first-page":"v602","DOI":"10.1093\/annonc\/mdz260","article-title":"1478O results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain","volume":"30","author":"Chow","year":"2019","journal-title":"Ann Oncol"},{"key":"R61-20260724","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"R62-20260724","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"key":"R63-20260724","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non\u2013small cell lung cancer: TRUST","volume":"43","author":"P\u00e9rol","year":"2025","journal-title":"J Clin Oncol"},{"key":"R64-20260724","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"R65-20260724","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J Clin Oncol"},{"key":"R66-20260724","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"R67-20260724","doi-asserted-by":"crossref","first-page":"107442","DOI":"10.1016\/j.lungcan.2023.107442","article-title":"Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer","volume":"188","author":"Cho","year":"2024","journal-title":"Lung Cancer"},{"key":"R68-20260724","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41591-025-04079-7","article-title":"Repotrectinib in NTRK fusion\u2013positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse","year":"2026","journal-title":"Nat Med"},{"key":"R69-20260724","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non\u2013small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"R70-20260724","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol"},{"key":"R71-20260724","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion\u2013positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"R72-20260724","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non\u2013small cell lung cancers on the LIBRETTO-001 trialintracranial efficacy of selpercatinib in RET fusion+ NSCLC","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R73-20260724","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion\u2013positive non\u2013small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"R74-20260724","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"R75-20260724","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in advanced HER2-mutant non\u2013small-cell lung cancer","volume":"393","author":"Le","year":"2025","journal-title":"N Engl J Med"},{"key":"R76-20260724","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non\u2013small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"key":"R77-20260724","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1016\/j.jtho.2025.09.1159","article-title":"PT2.12.03 zongertinib in patients with previously treated HER2-mutant NSCLC and brain metastases at baseline: Beamion LUNG-1","volume":"20","author":"Ruiter","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R78-20260724","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRASG12C-mutated non\u2013small-cell lung cancer who have untreated CNS metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"J Clin Oncol"},{"key":"R79-20260724","doi-asserted-by":"crossref","first-page":"S1123","DOI":"10.1016\/j.jtho.2021.08.547","article-title":"P52.03 efficacy of sotorasib in KRAS p.G12C-mutated NSCLC with stable brain metastases: a post-hoc analysis of CodeBreaK 100","volume":"16","author":"Ramalingam","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R80-20260724","doi-asserted-by":"crossref","first-page":"108683","DOI":"10.1016\/j.lungcan.2025.108683","article-title":"Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial","volume":"207","author":"Dingemans","year":"2025","journal-title":"Lung Cancer"},{"key":"R81-20260724","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.ijrobp.2023.06.869","article-title":"Upfront osimertinib alone vs. osimertinib and radiotherapy for the treatment of EGFR-positive NSCLC brain metastases: a multi-institutional series","volume":"117","author":"Dohm","year":"2023","journal-title":"Int J Radiat OncolBiolPhys"},{"key":"R82-20260724","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain metastases in EGFR- and ALK-positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R83-20260724","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R84-20260724","doi-asserted-by":"crossref","first-page":"100205","DOI":"10.1016\/j.jtocrr.2021.100205","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1\u2013positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Reports"},{"key":"R85-20260724","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"R86-20260724","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"key":"R87-20260724","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"R88-20260724","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"R89-20260724","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non\u2013small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"J Clin Oncol"},{"key":"R90-20260724","doi-asserted-by":"crossref","first-page":"103083","DOI":"10.1016\/j.ctrv.2025.103083","article-title":"Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: what have we accomplished so far?","volume":"143","author":"Cheo","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"R92-20260724","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R93-20260724","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2021","journal-title":"N Engl J Med"},{"key":"R94-20260724","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"R95-20260724","doi-asserted-by":"crossref","first-page":"e2543107","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab deruxtecan for ERBB2-mutant metastatic non\u2013small cell lung cancer with or without brain metastases","volume":"8","author":"J\u00e4nne","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R96-20260724","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"16_suppl","key":"R98-20260724","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.1200\/JCO.2024.42.16_suppl.8593","article-title":"Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced\/metastatic non-small cell lung cancer (a\/m NSCLC) with actionable genomic alterations (AGA): results from TROPION-Lung05","volume":"42","author":"Lisberg","year":"2024","journal-title":"J Clin Oncol"},{"key":"R99-20260724","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jtho.2025.09.061","article-title":"OA10.01 intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with advanced\/metastatic NSCLC in TROPION-Lung01","volume":"20","author":"Pons-Tostivint","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R100-20260724","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1080\/14796694.2024.2398983","article-title":"HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples","volume":"20","author":"Soo","year":"2024","journal-title":"Futur Oncol"},{"key":"R101-20260724","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1158\/1078-0432.CCR-08-2921","article-title":"HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors","volume":"15","author":"Sun","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R102-20260724","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor\u2013mutated non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"R103-20260724","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2025.43.16_suppl.8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J Clin Oncol"},{"key":"R104-20260724","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin monotherapy in patients with previously treated c-Met protein\u2013overexpressing advanced nonsquamous EGFR-wildtype non\u2013small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"key":"R105-20260724","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann Oncol"},{"key":"R106-20260724","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody\u2013drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol"},{"key":"R107-20260724","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S1556-0864(25)00324-7","article-title":"129TiP: A single arm phase II study evaluating intracranial efficacy of sacituzumab govitecan (SG) with bevacizumab (BEV) in patients (pts) with active, asymptomatic brain metastases (BM) from non-small cell lung cancer (NSCLC)","volume":"20","author":"Hendriks","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R108-20260724","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI\u2013resistant, EGFR-mutated advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N Engl J Med"},{"key":"R109-20260724","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(25)01954-3","article-title":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody\u2013drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China","volume":"406","author":"Yang","year":"2025","journal-title":"Lancet"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:40Z","timestamp":1784923240000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":105,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000840","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}